Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels

This study has been completed.
Information provided by:
Baskent University
ClinicalTrials.gov Identifier:
First received: August 27, 2007
Last updated: May 7, 2008
Last verified: May 2008
We aimed to evaluate the effects of rosiglitazone on serum ghrelin and peptide yy levels in diabetic women.

Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: rosiglitazone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels in Diabetic Women

Resource links provided by NLM:

Further study details as provided by Baskent University:


Ages Eligible for Study:   45 Years to 65 Years
Genders Eligible for Study:   Female

Inclusion Criteria:

  • newly diagnosed, drug naive women with type 2 diabetes

Exclusion Criteria:

  • presence of severe cardiovascular disease (eg, New York Heart Association class III or IV congestive heart failure or a history of myocardial infarction or stroke)
  • presence of thyroid, pituitary, nutritional, hepatic, renal, or neoplastic disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00522470

Baskent University Hospital Department of Endocrinology
Ankara, Bahçelievler, Turkey, 06490
Sponsors and Collaborators
Baskent University
Principal Investigator: Zehra Berberoglu, MD Baskent University Faculty of Medicine
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00522470     History of Changes
Other Study ID Numbers: KA 06/299 
Study First Received: August 27, 2007
Last Updated: May 7, 2008
Health Authority: Turkey: Ethics Committee

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 01, 2016